Search research articles
Contact Us
Filters
Showing results (261-270 of 278) with videos related to
Page
of 28
Sort By:
ACS Nano
|
July 28, 2025
Extracellular Vesicles for Clinical Diagnostics: From Bulk Measurements to Single-Vesicle Analysis
Hai Linh Tran, Wenshu Zheng, David A Issadore, et al.
Endoscopy
|
August 20, 2025
STAndardization of Reports (the STAR project) Upper gastrointestinal endoscopy: European Society of Gastrointestinal Endoscopy (ESGE) Quality Improvement Initiative
Gianluca Esposito, Miguel Areia, Hey-Long Ching, et al.
Gut
|
June 4, 2021
Residual SARS-CoV-2 viral antigens detected in GI and hepatic tissues from five recovered patients with COVID-19
Chun Chau Lawrence Cheung, Denise Goh, Xinru Lim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 25, 2026
Biomarker analysis from patients with metastatic PDAC treated with TGFβ antibody, NIS793, plus abraxane+gemcitabine vs. abraxane+gemcitabine alone in a phase II, open label, randomized study
Marc Pelletier, Jie Yang, Mukta Joshi, et al.
Immunity
|
July 16, 2021
Non-terminally exhausted tumor-resident memory HBV-specific T cell responses correlate with relapse-free survival in hepatocellular carcinoma
Yang Cheng, Bavani Gunasegaran, Harsimran D Singh, et al.
Cancer Reports (Hoboken, N.J.)
|
May 3, 2021
Resected pancreatic adenocarcinoma: An Asian institution's experience
Kennedy Yao Yi Ng, Edwin Wei Xiang Chow, Bochao Jiang, et al.
Journal of Hepatology
|
April 17, 2022
Uncoupling immune trajectories of response and adverse events from anti-PD-1 immunotherapy in hepatocellular carcinoma
Samuel Chuah, Joycelyn Lee, Yuan Song, et al.
Future Oncology (London, England)
|
April 15, 2026
A plain language summary of the CheckMate 9DW study: nivolumab in combination with ipilimumab for unresectable hepatocellular carcinoma (advanced liver cancer)
Thomas Yau, Peter R Galle, Thomas Decaens, et al.
Lancet (London, England)
|
May 11, 2025
Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial
Thomas Yau, Peter R Galle, Thomas Decaens, et al.
Journal for Immunotherapy of Cancer
|
August 28, 2020
Immunohistochemical scoring of CD38 in the tumor microenvironment predicts responsiveness to anti-PD-1/PD-L1 immunotherapy in hepatocellular carcinoma
Harry Ho Man Ng, Ren Yuan Lee, Siting Goh, et al.
Page
of 28
Search research articles
Search
Showing results (261-270 of 278) with videos related to
Sort By:
Page
of 28
ACS Nano
|
July 28, 2025
Extracellular Vesicles for Clinical Diagnostics: From Bulk Measurements to Single-Vesicle Analysis
Hai Linh Tran, Wenshu Zheng, David A Issadore, et al.
Endoscopy
|
August 20, 2025
STAndardization of Reports (the STAR project) Upper gastrointestinal endoscopy: European Society of Gastrointestinal Endoscopy (ESGE) Quality Improvement Initiative
Gianluca Esposito, Miguel Areia, Hey-Long Ching, et al.
Gut
|
June 4, 2021
Residual SARS-CoV-2 viral antigens detected in GI and hepatic tissues from five recovered patients with COVID-19
Chun Chau Lawrence Cheung, Denise Goh, Xinru Lim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 25, 2026
Biomarker analysis from patients with metastatic PDAC treated with TGFβ antibody, NIS793, plus abraxane+gemcitabine vs. abraxane+gemcitabine alone in a phase II, open label, randomized study
Marc Pelletier, Jie Yang, Mukta Joshi, et al.
Immunity
|
July 16, 2021
Non-terminally exhausted tumor-resident memory HBV-specific T cell responses correlate with relapse-free survival in hepatocellular carcinoma
Yang Cheng, Bavani Gunasegaran, Harsimran D Singh, et al.
Cancer Reports (Hoboken, N.J.)
|
May 3, 2021
Resected pancreatic adenocarcinoma: An Asian institution's experience
Kennedy Yao Yi Ng, Edwin Wei Xiang Chow, Bochao Jiang, et al.
Journal of Hepatology
|
April 17, 2022
Uncoupling immune trajectories of response and adverse events from anti-PD-1 immunotherapy in hepatocellular carcinoma
Samuel Chuah, Joycelyn Lee, Yuan Song, et al.
Future Oncology (London, England)
|
April 15, 2026
A plain language summary of the CheckMate 9DW study: nivolumab in combination with ipilimumab for unresectable hepatocellular carcinoma (advanced liver cancer)
Thomas Yau, Peter R Galle, Thomas Decaens, et al.
Lancet (London, England)
|
May 11, 2025
Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial
Thomas Yau, Peter R Galle, Thomas Decaens, et al.
Journal for Immunotherapy of Cancer
|
August 28, 2020
Immunohistochemical scoring of CD38 in the tumor microenvironment predicts responsiveness to anti-PD-1/PD-L1 immunotherapy in hepatocellular carcinoma
Harry Ho Man Ng, Ren Yuan Lee, Siting Goh, et al.
Page
of 28